PR Newswire
AMGEN TO PRESENT AT THE 46TH ANNUAL TD COWEN HEALTH CARE CONFERENCE
📊
AI Sentiment
Positive
7/10
- Home
- AMGN
AMGN
Amgen Inc.
as of 02-26-2026 9:36am EST
$382.30
$1.75
-0.46%
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
| Founded: | 1980 | Country: | United States |
| Employees: | N/A | City: | THOUSAND OAKS |
| Market Cap: | 202.4B | IPO Year: | 1999 |
| Target Price: | $345.12 | AVG Volume (30 days): | 2.7M |
| Analyst Decision: | Hold | Number of Analysts: | 18 |
| Dividend Yield: | Dividend Payout Frequency: | quarterly | |
| EPS: | 14.23 | EPS Growth: | 88.23 |
| 52 Week Low/High: | $265.66 - $387.49 | Next Earning Date: | 05-05-2026 |
| Revenue: | $25,424,000,000 | Revenue Growth: | 8.83% |
| Revenue Growth (this year): | 4.88% | Revenue Growth (next year): | 2.58% |
| P/E Ratio: | 26.99 | Index: | |
| Free Cash Flow: | 8.1B | FCF Growth: | -22.07% |
Latest Amgen Inc. News
AMGN Breaking Stock News: Dive into AMGN Ticker-Specific Updates for Smart Investing
Insider Monkey
Viking Therapeutics, Inc. (VKTX): A Bull Case Theory
📈
AI Sentiment
Highly Positive
8/10
Simply Wall St.
Amgen (AMGN) Valuation Check After Recent Share Price Strength And Analyst Fair Value Debate
📊
AI Sentiment
Positive
7/10
StockStory
1 Unpopular Stock That Deserves a Second Chance and 2 We Turn Down
📉
AI Sentiment
Negative
3/10
Insider Monkey
Barclays Begins Amgen (AMGN) Coverage, Notes Balanced Outlook Despite Trial Debate
📈
AI Sentiment
Highly Positive
8/10
Zacks
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It
📊
AI Sentiment
Positive
6/10
24/7 Wall St.
Here Are Friday’s Top Wall Street Analyst Research Calls: Amgen, ETSY, Eldorado Gold, GE Aerospace, Merck, Southern Company, Walmart, Yeti, and More
➖
AI Sentiment
Neutral
4/10
Compare AMGN vs Leading Stocks
See how AMGN stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "AMGN Amgen Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.